We sought to compare the in vitro drug delivery characteristics, delivered dose uniformity, mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of two budesonide/formoterol multidose dry powder inhalers, Bufomix Easyhaler ® (Orion Corporation Orion Pharma) and Symbicort ® Turbuhaler ® (Astra Zeneca) at different patient air flow rates.
Methods
We used commercially available Easyhaler and Turbuhaler products containing 160/4.5 µg per dose of budesonide and formoterol. A total of 36 inhalers from two batches of both products were used when comparing the effect of flow rate; six inhalers for each of the three flow rates for uniformity of the delivered dose, MMAD and GSD. Delivered dose consistency and MMAD were determined for each inhaler at three different flow rates: 10 th , 50 th and 90 th percentile air flows 1 (Table 1) . 
Results

Conclusions
Figures 1 and 2 show the delivered doses of budesonide ( Fig.1 ) and formoterol ( Fig.2 ) at different flow rates expressed as percent of the labelled doses. The variability in dose delivery from Easyhaler was statistically significantly smaller than from Turbuhaler for both budesonide and formoterol (p<0.001, the three flow rates combined).
Easyhaler showed significantly better dose consistency (expressed as percent of labelled dose) at all three inhalation flows compared with Turbuhaler (p<0.001 for three flow rates combined). In vitro performance indicates reliable dosing of Easyhaler. MMAD and GSD were comparable for the two inhalers and substances based on relevant air flow rates. The delivered dose from each inhaler was determined by drawing air through the actuated inhaler onto a filter. 3 Amount of active drug collected on the filter was determined by high performance liquid chromatography (HPLC). Dose delivery was measured at 10th percentile, 50th (i.e. median) and 90th percentiles of the achievable air flow rates. Individual doses were analysed at each flow rate.
Presented at ERS
Delivered dose
Mass Median Aerodynamic Diameter (MMAD) and geometric standard deviation (GSD)
MMAD and GSD values were determined from the measurements at the same flow rates (Table 1) . MMAD and GSD values are calculated from the number of particles depositing at different stages of the Next Generation Impactor (NGI). 3 The respective stage cut-off values are disclosed in Table 2 . 
Statistical analyses
Mean values and standard deviations (SD) were calculated for the delivered doses from budesonide/formoterol Easyhaler and Turbuhaler at the three different flow rates. The equality of variances was assessed for all different flow rates using Levene's test due non-normality of data with significance level of 0.05. The null hypothesis of equal variances is rejected with p -values less than significance level and it is concluded that there is a statistically significant difference between the variances. All statistical analyses were performed with Minitab version 17 (Minitab Inc, State College Pennsylvania, US).
Delivered dose
MMAD values and geometric standard deviations (GSD) for budesonide/formoterol Easyhaler and budesonide/formoterol Turbuhaler at different flow rates are presented in Table 3 . Higher flows resulted in lower MMADs for both inhalers when going from the 10th percentile of flow rates to the 90th percentile. For budesonide MMAD decreased for Easyhaler from 2.5 to 2.2 µm and for Turbuhaler from 2.5 to 2.1 µm. The corresponding values for formoterol were from 3.0 to 2.7 µm for Easyhaler, and from 2.7 to 2.2 µm for Turbuhaler. GSD's of the particle size distributions were the same between the products through the different flow rates. 
Mass median aerodynamic diameter (µm) and geometric standard deviation
